Pacira Other Stockholder Equity from 2010 to 2024

PCRX Stock  USD 17.38  0.35  2.06%   
Pacira BioSciences, Other Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Other Stockholder Equity will likely drop to about 599.8 M in 2024. During the period from 2010 to 2024, Pacira BioSciences, Other Stockholder Equity regression line of annual values had r-squared of  0.78 and arithmetic mean of  609,240,017. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2009-12-31
Previous Quarter
958.1 M
Current Value
971.3 M
Quarterly Volatility
279.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pacira BioSciences, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacira BioSciences,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 79.4 M, Interest Expense of 15.8 M or Selling General Administrative of 63.1 M, as well as many indicators such as Price To Sales Ratio of 2.19, Dividend Yield of 0.0014 or PTB Ratio of 1.7. Pacira financial statements analysis is a perfect complement when working with Pacira BioSciences, Valuation or Volatility modules.
  
Check out the analysis of Pacira BioSciences, Correlation against competitors.
For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.

Latest Pacira BioSciences,'s Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Pacira BioSciences, over the last few years. It is Pacira BioSciences,'s Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacira BioSciences,'s overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Pacira Other Stockholder Equity Regression Statistics

Arithmetic Mean609,240,017
Geometric Mean525,860,551
Coefficient Of Variation44.71
Mean Deviation217,706,251
Median602,687,000
Standard Deviation272,398,047
Sample Variance74200.7T
Range887.9M
R-Value0.88
Mean Square Error17414.9T
R-Squared0.78
Significance0.000012
Slope53,865,428
Total Sum of Squares1038809.7T

Pacira Other Stockholder Equity History

2024599.8 M
2023976.6 M
2022924.1 M
2021942.1 M
2020873.2 M
2019754 M
2018709.7 M

About Pacira BioSciences, Financial Statements

Pacira BioSciences, investors use historical fundamental indicators, such as Pacira BioSciences,'s Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pacira BioSciences,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity976.6 M599.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.